A Double Blind, Placebo- controlled Trial of Rosiglitazone for Clozapine induced Glucose Metabolism Impairment in patients with Schizophrenia

OBJECTIVE: The primary purpose of this eight week double blind, placebo-controlled trial of rosiglitazone 4 mg/day was to examine its effect on insulin sensitivity index (SI) and glucose utilization (SG) in clozapine-treated schizophrenia subjects with insulin resistance. METHODS: Eighteen subjects...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Acta Psychiatr Scand
Auteurs principaux: Henderson, David C., Fan, Xiaoduo, Sharma, Bikash, Copeland, Paul M., Borba, Christina P, Boxill, Ryan, Freudenreich, Oliver, Cather, Corey, Evins, A. Eden, Goff, Donald C.
Format: Artigo
Langue:Inglês
Publié: 2009
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4296018/
https://ncbi.nlm.nih.gov/pubmed/19183127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1600-0447.2008.01325.x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires